Adial Pharmaceuticals Inc. [NASDAQ: ADIL] gained 10.56% or 0.19 points to close at $1.99 with a heavy trading volume of 1123442 shares. The company report on November 3, 2020 that Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder.
ONWARD™ Projected to be Fully Enrolled During Q2 2021.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, provided an update on its landmark ONWARD™ Phase 3 pivotal trial. ONWARD™ is investigating Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.
It opened the trading session at $1.78, the shares rose to $2.04 and dropped to $1.75, the range by which the price of stock traded the whole day. The daily chart for ADIL points out that the company has recorded 46.32% gains over the past six months. However, it is still -99.0% lower than its most recent low trading price.
If we look at the average trading volume of 2.49M shares, ADIL reached to a volume of 1123442 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adial Pharmaceuticals Inc. [ADIL]:
Maxim Group have made an estimate for Adial Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 30, 2018. The new note on the price target was released on October 11, 2018, representing the official price target for Adial Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Adial Pharmaceuticals Inc. is set at 0.14 The Price to Book ratio for the last quarter was 2.55, with the Price to Cash per share for the same quarter was set at 0.65.
Trading performance analysis for ADIL stock
Adial Pharmaceuticals Inc. [ADIL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.56. With this latest performance, ADIL shares gained by 2.58% in over the last four-week period, additionally plugging by 46.32% over the last 6 months – not to mention a rise of 21.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADIL stock in for the last two-week period is set at 60.28, with the RSI for the last a single of trading hit 64.84, and the three-weeks RSI is set at 56.56 for Adial Pharmaceuticals Inc. [ADIL]. The present Moving Average for the last 50 days of trading for this stock 1.7206, while it was recorded at 1.8240 for the last single week of trading, and 1.5357 for the last 200 days.
Adial Pharmaceuticals Inc. [ADIL]: A deeper dive into fundamental analysis
Return on Total Capital for ADIL is now -142.38, given the latest momentum, and Return on Invested Capital for the company is -148.36. Return on Equity for this stock declined to -148.36, with Return on Assets sitting at -138.81.
Reflecting on the efficiency of the workforce at the company, Adial Pharmaceuticals Inc. [ADIL] managed to generate an average of -$2,147,857 per employee.Adial Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.90 and a Current Ratio set at 13.90.
Adial Pharmaceuticals Inc. [ADIL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adial Pharmaceuticals Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADIL.
An analysis of insider ownership at Adial Pharmaceuticals Inc. [ADIL]
There are presently around $2 million, or 11.30% of ADIL stock, in the hands of institutional investors. The top three institutional holders of ADIL stocks are: VANGUARD GROUP INC with ownership of 282,909, which is approximately 0% of the company’s market cap and around 18.82% of the total institutional ownership; BLACKROCK INC., holding 205,684 shares of the stock with an approximate value of $0.41 million in ADIL stocks shares; and BANK OF AMERICA CORP /DE/, currently with $0.3 million in ADIL stock with ownership of nearly New of the company’s market capitalization.
Positions in Adial Pharmaceuticals Inc. stocks held by institutional investors increased at the end of September and at the time of the September reporting period, where 6 institutional holders increased their position in Adial Pharmaceuticals Inc. [NASDAQ:ADIL] by around 237,474 shares. Additionally, 1 investors decreased positions by around 13,714 shares, while 7 investors held positions by with 601,362 shares. The mentioned changes placed institutional holdings at 852,550 shares, according to the latest SEC report filing. ADIL stock had 4 new institutional investments in for a total of 231,295 shares, while 1 institutional investors sold positions of 13,714 shares during the same period.